Signaturefd LLC Has $35,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Signaturefd LLC grew its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 40.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 319 shares of the medical equipment provider’s stock after buying an additional 92 shares during the quarter. Signaturefd LLC’s holdings in Lantheus were worth $35,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of LNTH. GAMMA Investing LLC grew its stake in shares of Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 208 shares in the last quarter. Fidelis Capital Partners LLC acquired a new stake in Lantheus in the first quarter valued at $34,000. FinTrust Capital Advisors LLC lifted its stake in Lantheus by 53.6% in the first quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock valued at $41,000 after acquiring an additional 232 shares during the last quarter. Nkcfo LLC bought a new position in shares of Lantheus in the 2nd quarter valued at about $47,000. Finally, UMB Bank n.a. increased its stake in shares of Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Lantheus

In other news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the sale, the president now directly owns 98,980 shares in the company, valued at $9,540,682.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 27,981 shares of company stock valued at $2,689,156 in the last quarter. Company insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on LNTH shares. Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company. Leerink Partners lifted their target price on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. JMP Securities dropped their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 1st. Truist Financial cut their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Finally, B. Riley upped their price objective on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $109.38 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The firm has a market cap of $7.58 billion, a price-to-earnings ratio of 16.83 and a beta of 0.50. The stock’s fifty day moving average price is $107.80 and its two-hundred day moving average price is $93.85. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. During the same quarter last year, the company posted $1.40 earnings per share. The company’s revenue was up 22.5% on a year-over-year basis. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.